

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS INC., DR REDDY’S LABORATORIES, INC.,
DR. REDDY’S LABORATORIES, LTD., SUN PHARMACEUTICAL
INDUSTRIES LTD., AND SUN PHARMACEUTICAL INDUSTRIES, INC.,
Petitioner,

v.

NOVO NORDISK A/S,
Patent Owner.

Case No. IPR2023-00724¹

Patent No. 10,335,462

PETITIONER’S MOTION TO SEAL

¹ IPR2024-00009 (Dr. Reddy’s Laboratories) and IPR2024-00107 (Sun Pharmaceutical Industries) have been joined with this proceeding.

I. Introduction

Under 37 C.F.R. §§ 42.14 and 42.54, Petitioner moves to seal its Petitioner's Oral Hearing Demonstratives, Exhibit 1334, and Petitioner's Objections to Patent Owner's Demonstrative Exhibits, Paper 94. Patent Owner has advised Petitioner that it does not oppose this motion to seal.

II. Good cause exists to seal Exhibit 1334 and Paper 94.

Under the stipulated protective order and 37 C.F.R. § 42.14, Petitioner moves to seal its (i) Petitioner's Oral Hearing Demonstratives, Exhibit 1334; and (ii) Petitioner's Objections to Patent Owner's Demonstrative Exhibits, Paper 94.

As the Board found in similar cases, "good cause" exists to seal Petitioner's Oral Hearing Demonstratives because they include Patent Owner's non-public business information. *Celltrion, Inc. v. Genentech, Inc.*, IPR2016-01667, Paper 31, 4 (July 23, 2018); *Greene's Energy Grp., LLC v. Oil States Energy Servs., LLC*, IPR2014-00216, Paper 27, 5 (Sept. 23, 2014); 37 C.F.R. § 42.54.

Exhibit 1334 contains material previously designated by Patent Owner as containing protective order material. Patent Owner has previously designated its Patent Owner's Demonstrative Exhibits as protective order material. Because Petitioner's Objections to Patent Owner's Demonstrative Exhibits addresses this designated protective order material, it is necessary to file under seal.

Petitioner has already filed redacted versions of both its Petitioner's Oral Hearing Demonstrative and Petitioner's Objections to Patent Owner's Demonstrative Exhibits. The latter is Paper 95.

III. Conclusion

For the foregoing reasons, Petitioner respectfully requests that the Board grant this motion to seal.

Dated: September 4, 2024

PERKINS COIE LLP
700 Thirteenth Street, N.W., Suite 800
Washington, D.C. 20005-3960
202.654.6200 (phone)
202.654.6211 (fax)

Respectfully submitted,

/Brandon M. White/

Lead Counsel
Brandon M. White, Reg No. 52,354

Attorneys for Petitioner

CERTIFICATE OF SERVICE

Pursuant to 37 C.F.R. § 42.6(e), I certify that I caused to be served a true and correct copy of the foregoing: PETITIONER'S MOTION TO SEAL by email to the electronic service addresses for Patent Owner and Petitioner in IPR2024-00009 and IPR2024-00107:

J. Steven Baughman
Megan Raymond
Jenny C. Wu
Michael Milea
Philip S. May
Joshua Reich
GROOMBRIDGE, WU, BAUGHMAN &
STONE LLP
steve.baughman@groombridgewu.com
megan.raymond@groombridgewu.com
jenny.wu@groombridgewu.com
mike.milea@groombridgewu.com
philip.may@groombridgewu.com
Joshua.reich@groombridgewu.com
Novo-Semaglutide-
IPR@groombridgewu.com

Jovial Wong
Scott Border
WINSTON & STRAWN LLC
jwong@winston.com
sborder@winston.com

Brian Sodikoff
Christopher B. Ferenc
KATTEN MUCHIN ROSENMAN LLP
brian.sodikoff@katten.com
christopher.ferenc@katten.com

Dated: September 4, 2024

PERKINS COIE LLP
700 Thirteenth Street, N.W., Suite 800
Washington, D.C. 20005-3960
202.654.6200 (phone)
202.654.6211 (fax)

/Brandon M. White/

Lead Counsel
Brandon M. White, Reg No. 52,354

Attorneys for Petitioner